| NKCx Histopathological outcome* within 12 months after cervix cytology in 2024 |
| 131 Sörmland |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 34 | 10.7% | 18 | 5.7% | 14 | 4.4% | . | . | . | . | 1 | 0.3% | 250 | 78.9% | 317 | 100.0% |
| ASCUS | 102 | 30.4% | 131 | 39.0% | 57 | 17.0% | 1 | 0.3% | . | . | 7 | 2.1% | 38 | 11.3% | 336 | 100.0% |
| LSIL | 77 | 24.8% | 135 | 43.4% | 66 | 21.2% | . | . | 2 | 0.6% | 1 | 0.3% | 30 | 9.6% | 311 | 100.0% |
| Atypical glandular cells/AGC | . | . | 1 | 50.0% | . | . | . | . | 1 | 50.0% | . | . | . | . | 2 | 100.0% |
| Unclear atypia | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | . | . | 1 | 100.0% |
| ASC-H | 9 | 19.1% | 12 | 25.5% | 23 | 48.9% | 3 | 6.4% | . | . | . | . | . | . | 47 | 100.0% |
| HSIL | 2 | 4.8% | 3 | 7.1% | 33 | 78.6% | 1 | 2.4% | 1 | 2.4% | 1 | 2.4% | 1 | 2.4% | 42 | 100.0% |
| Totalt | 224 | 21.2% | 301 | 28.5% | 193 | 18.3% | 5 | 0.5% | 4 | 0.4% | 10 | 0.9% | 319 | 30.2% | 1056 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M80703, M81403 |